2017 was a good year for biotechs looking to raise money. Venture capital investment in biotech companies reached the stratospheric levels of $16 billion. And it was not only seasoned companies that benefitted—the largesse extended to companies raising their first rounds, which accounted for nearly a third of risk capital entering the sector.

Para acessar a publicação na íntegra clique aqui

Fonte: NATURE BIOTECHNOLOGY VOLUME 36 NUMBER 4 APRIL 2018